Pharming Capital Stock from 2010 to 2024

PHAR Stock

USD 7.65 0.12 1.59%

Pharming Group Capital Stock yearly trend continues to be relatively stable with very little volatility. Capital Stock is likely to grow to about 8.2 M this year. Capital Stock is the total amount of a company's capital funded by shareholders through the issue and subscription of shares. View All Fundamentals

Capital Stock

First Reported

2010-12-31

Previous Quarter

7.7 M

Current Value

8.2 M

Quarterly Volatility

345 K

Credit Downgrade

Yuan Drop

Covid

Check Pharming Group financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pharming Group's main balance sheet or income statement drivers, such as Depreciation And Amortization of 16.7 M, Interest Expense of 6.4 M or Selling And Marketing Expenses of 6.5 M, as well as many indicators such as Price To Sales Ratio of 2.62, Dividend Yield of 0.0 or PTB Ratio of 3.07. Pharming financial statements analysis is a perfect complement when working with Pharming Group Valuation or Volatility modules.

Check out the analysis of Pharming Group Correlation against competitors.

Latest Pharming Group's Capital Stock Growth Pattern

Below is the plot of the Capital Stock of Pharming Group NV over the last few years. It is the total amount of a company's capital funded by shareholders through the issue and subscription of shares. Pharming Group's Capital Stock historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Pharming Group's overall financial position and show how it may be relating to other accounts over time.

Capital Stock

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Capital Stock

Timeline

Pharming Capital Stock Regression Statistics

	Arithmetic Mean	7,313,646
	Geometric Mean	7,306,355
	Coefficient Of Variation	4.72
	Mean Deviation	277,414
	Median	7,109,357
	Standard Deviation	344,981
	Sample Variance	119B
	Range	1.1M
	R-Value	0.76
	Mean Square Error	54.9B
	R-Squared	0.57
	Significance	0
	Slope	58,324
	Total Sum of Squares	1.7T

Pharming Capital Stock History

	2024	8.2 M
	2023	7.7 M
	2022	7.5 M
	2021	7.4 M
	2020	7.9 M
	2019	7.1 M

Other Fundumenentals of Pharming Group NV

Issuance Of Capital Stock

Pharming Group Capital Stock component correlations

	Total Assets	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Short Term Investments	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Good Will	Net Tangible Assets	Long Term Debt	Deferred Long Term Liab	Net Invested Capital	Short Long Term Debt	Net Working Capital	Property Plant Equipment	Capital Stock	Long Term Investments
Total Assets		0.97	0.19	0.38	0.23	0.7	0.91	0.58	0.97	0.99	0.09	0.81	-0.36	-0.28	0.95	0.68	-0.71	0.92	-0.63	0.84	0.87	0.83	0.79
Total Stockholder Equity	0.97		0.19	0.32	0.42	0.59	0.86	0.6	0.88	0.98	-0.04	0.71	-0.26	-0.17	0.98	0.71	-0.73	0.95	-0.67	0.88	0.91	0.85	0.84
Current Deferred Revenue	0.19	0.19		-0.31	-0.14	0.28	0.26	-0.2	0.18	0.11	0.39	0.41	-0.12	-0.12	0.1	-0.19	0.49	0.08	0.23	-0.08	-0.12	0.12	-0.28
Net Debt	0.38	0.32	-0.31		0.07	0.42	0.57	0.89	0.41	0.41	0.05	0.12	-0.1	-0.11	0.41	0.2	-0.46	0.27	-0.27	0.27	0.55	0.49	0.46
Retained Earnings	0.23	0.42	-0.14	0.07		-0.11	0.13	0.3	0.03	0.3	-0.43	-0.02	0.46	0.57	0.38	0.44	-0.39	0.41	-0.45	0.44	0.44	0.33	0.47
Accounts Payable	0.7	0.59	0.28	0.42	-0.11		0.69	0.47	0.77	0.67	0.2	0.72	-0.26	-0.13	0.55	0.47	-0.25	0.58	-0.39	0.54	0.46	0.56	0.4
Net Receivables	0.91	0.86	0.26	0.57	0.13	0.69		0.68	0.9	0.87	0.37	0.77	-0.37	-0.28	0.87	0.38	-0.59	0.75	-0.33	0.62	0.79	0.71	0.67
Short Term Investments	0.58	0.6	-0.2	0.89	0.3	0.47	0.68		0.52	0.65	-0.17	0.15	-0.09	-0.07	0.68	0.43	-0.63	0.54	-0.48	0.53	0.78	0.73	0.67
Total Liab	0.97	0.88	0.18	0.41	0.03	0.77	0.9	0.52		0.94	0.21	0.87	-0.43	-0.36	0.87	0.61	-0.64	0.83	-0.55	0.76	0.77	0.76	0.7
Total Current Assets	0.99	0.98	0.11	0.41	0.3	0.67	0.87	0.65	0.94		-0.05	0.72	-0.34	-0.26	0.97	0.75	-0.76	0.94	-0.72	0.89	0.91	0.88	0.84
Short Term Debt	0.09	-0.04	0.39	0.05	-0.43	0.2	0.37	-0.17	0.21	-0.05		0.47	-0.27	-0.2	-0.07	-0.59	0.22	-0.19	0.67	-0.35	-0.21	-0.3	-0.27
Intangible Assets	0.81	0.71	0.41	0.12	-0.02	0.72	0.77	0.15	0.87	0.72	0.47		-0.39	-0.29	0.65	0.4	-0.35	0.67	-0.29	0.57	0.48	0.44	0.45
Common Stock	-0.36	-0.26	-0.12	-0.1	0.46	-0.26	-0.37	-0.09	-0.43	-0.34	-0.27	-0.39		0.88	-0.26	-0.12	0.18	-0.24	0.1	-0.2	-0.21	-0.19	-0.19
Good Will	-0.28	-0.17	-0.12	-0.11	0.57	-0.13	-0.28	-0.07	-0.36	-0.26	-0.2	-0.29	0.88		-0.22	-0.11	0.15	-0.21	0.09	-0.17	-0.18	-0.16	-0.16
Net Tangible Assets	0.95	0.98	0.1	0.41	0.38	0.55	0.87	0.68	0.87	0.97	-0.07	0.65	-0.26	-0.22		0.71	-0.8	0.95	-0.67	0.89	0.96	0.85	0.89
Long Term Debt	0.68	0.71	-0.19	0.2	0.44	0.47	0.38	0.43	0.61	0.75	-0.59	0.4	-0.12	-0.11	0.71		-0.68	0.85	-0.97	0.94	0.74	0.72	0.8
Deferred Long Term Liab	-0.71	-0.73	0.49	-0.46	-0.39	-0.25	-0.59	-0.63	-0.64	-0.76	0.22	-0.35	0.18	0.15	-0.8	-0.68		-0.77	0.65	-0.79	-0.87	-0.59	-0.93
Net Invested Capital	0.92	0.95	0.08	0.27	0.41	0.58	0.75	0.54	0.83	0.94	-0.19	0.67	-0.24	-0.21	0.95	0.85	-0.77		-0.77	0.97	0.9	0.78	0.91
Short Long Term Debt	-0.63	-0.67	0.23	-0.27	-0.45	-0.39	-0.33	-0.48	-0.55	-0.72	0.67	-0.29	0.1	0.09	-0.67	-0.97	0.65	-0.77		-0.86	-0.73	-0.78	-0.75
Net Working Capital	0.84	0.88	-0.08	0.27	0.44	0.54	0.62	0.53	0.76	0.89	-0.35	0.57	-0.2	-0.17	0.89	0.94	-0.79	0.97	-0.86		0.88	0.75	0.92
Property Plant Equipment	0.87	0.91	-0.12	0.55	0.44	0.46	0.79	0.78	0.77	0.91	-0.21	0.48	-0.21	-0.18	0.96	0.74	-0.87	0.9	-0.73	0.88		0.83	0.96
Capital Stock	0.83	0.85	0.12	0.49	0.33	0.56	0.71	0.73	0.76	0.88	-0.3	0.44	-0.19	-0.16	0.85	0.72	-0.59	0.78	-0.78	0.75	0.83		0.68
Long Term Investments	0.79	0.84	-0.28	0.46	0.47	0.4	0.67	0.67	0.7	0.84	-0.27	0.45	-0.19	-0.16	0.89	0.8	-0.93	0.91	-0.75	0.92	0.96	0.68

Click cells to compare fundamentals

About Pharming Group Financial Statements

Pharming Group shareholders use historical fundamental indicators, such as Capital Stock, to determine how well the company is positioned to perform in the future. Although Pharming Group investors may analyze each financial statement separately, they are all interrelated. The changes in Pharming Group's assets and liabilities, for example, are also reflected in the revenues and expenses on on Pharming Group's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

	Last Reported	Projected for Next Year
Capital Stock	7.7 M	8.2 M
Issuance Of Capital Stock	2.1 M	4 M

Additional Tools for Pharming Stock Analysis

When running Pharming Group's price analysis, check to measure Pharming Group's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharming Group is operating at the current time. Most of Pharming Group's value examination focuses on studying past and present price action to predict the probability of Pharming Group's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharming Group's price. Additionally, you may evaluate how the addition of Pharming Group to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Pharming Capital Stock from 2010 to 2024

Latest Pharming Group's Capital Stock Growth Pattern

Pharming Capital Stock Regression Statistics

Pharming Capital Stock History

Other Fundumenentals of Pharming Group NV

Pharming Group Capital Stock component correlations

About Pharming Group Financial Statements

Additional Tools for Pharming Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY